Legend Biotech Corp (LEGN) — SEC Filings
Legend Biotech Corp (LEGN) — 50 SEC filings. Latest: 6-K (Apr 14, 2026). Includes 45 6-K, 3 SC 13G/A, 2 20-F.
View Legend Biotech Corp on SEC EDGAR
Overview
Legend Biotech Corp (LEGN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Apr 14, 2026: Legend Biotech Corp. filed a Form 6-K on April 14, 2026, reporting information as a foreign issuer. The filing includes standard corporate information such as mailing and business addresses in Somerset, NJ, and identifies the company's CIK as 0001801198. The report is categorized under Pharmaceutica
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 11 bullish, 39 neutral. The dominant filing sentiment for Legend Biotech Corp is neutral.
Filing Type Overview
Legend Biotech Corp (LEGN) has filed 45 6-K, 2 20-F, 3 SC 13G/A with the SEC between Mar 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of LEGN's 46 recent filings, 0 were flagged as high-risk, 6 as medium-risk, and 40 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Key Executives
- Peter Salovey, Ph.D.
- Lori Macomber
Industry Context
Legend Biotech Corp operates in the pharmaceutical preparations industry, focusing on the development and commercialization of novel cell therapies for cancer and other serious diseases.
Top Tags
sec-filing (15) · foreign-private-issuer (8) · 6-K (6) · sales-update (6) · collaboration (6) · pharmaceutical (6) · shareholder-meeting (4) · financial-update (4) · corporate-governance (4) · oncology (4)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Reporting Period End Date | 2025-09-30 | Covers Q3 2025 financial data. |
| Filing Date | 2025-11-12 | Date the 6-K was submitted to the SEC. |
| CARVYKTI® Net Sales | $524 million | Preliminary sales for the quarter ended September 30, 2025 |
| New Headquarters Space | 57,325 sq ft | Size of the leased office space in Bridgewater, NJ. |
| Reporting Period | 2025 Q1 | Financial data presented for the first quarter of 2025. |
| Previous Year End | 2024-12-31 | Comparative financial data from the end of 2024. |
| CARVYKTI® Net Trade Sales | $369 million | For the quarter ended March 31, 2025 |
| Fiscal Year End | 2024-12-31 | Reporting period for the 20-F filing. |
| Prior Year End | 2021-12-31 | Includes financial data from this period. |
| As of Date | 2024-09-30 | Key financial figures are reported as of this date. |
| First Half 2024 | 2024-01-01 to 2024-06-30 | Represents the cumulative financial activity for the first six months of 2024. |
| Fiscal Year Start | 2023-01-01 | The report covers the period starting on this date. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Legend Biotech Corp (LEGN)?
Legend Biotech Corp has 50 recent SEC filings from Mar 2024 to Apr 2026, including 45 6-K, 3 SC 13G/A, 2 20-F. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of LEGN filings?
Across 50 filings, the sentiment breakdown is: 11 bullish, 39 neutral. The dominant sentiment is neutral.
Where can I find Legend Biotech Corp SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Legend Biotech Corp (LEGN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Legend Biotech Corp?
Financial highlights for Legend Biotech Corp are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for LEGN?
The investment thesis for LEGN includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Legend Biotech Corp?
Key executives identified across Legend Biotech Corp's filings include Peter Salovey, Ph.D., Lori Macomber.
What are the main risk factors for Legend Biotech Corp stock?
Of LEGN's 46 assessed filings, 0 were flagged high-risk, 6 medium-risk, and 40 low-risk.
What are recent predictions and forward guidance from Legend Biotech Corp?
Forward guidance and predictions for Legend Biotech Corp are extracted from SEC filings as they are enriched.